Clinical trial
Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients
NCT00395291 · University of Virginia, Other · Completed
Key facts
| NCT number | NCT00395291 |
|---|---|
| Title | Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients |
| Official title | Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients |
| Lead sponsor | University of Virginia, Other |
| Collaborators | National Institutes of Health (NIH) NIH Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Chronic Kidney Disease, End Stage Renal Disease |
| Intervention type | Drug |
| Interventions | MK-0677, Placebo |
| Enrollment | 49 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | May 1, 2010 |
| First posted | Nov 2, 2006 |
| Last update posted | Feb 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: